Hcw Biologics Inc (HCWB) Stock Price, Quote & News

Company Profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia are...

Industry: Biotechnology

Sector: Healthcare

Phone: 954 842 2024

Fax: 954 842 2037

Website: www.hcwbiologics.com

Address:

2929 North Commerce Parkway, Miramar, United States

Pennywarehouse Sep. 16 at 11:26 AM

$HCWB Going to buy but at 0.66 !

0 · Reply

SpanishSpolied75 Sep. 15 at 8:00 PM

$HCWB — SILENCED ON REDDIT FOR EXPOSING SHORT MECHANICS! 🚨🐻Reddit mods deleted this DD after 6K views. Why? Because the mathematical noose around shorts at $2.20 is real:1️⃣ DRY FLOAT: Total active worldwide float is a mere 387,682 shares. They are running completely out of physical ammunition.2️⃣ 463% CTB: Maintaining the cap is financial suicide. Shorts are burning a fortune in a 463% annual borrow fee just to keep the lid on.3️⃣ THE TRAP: Proposal 1 is their escape hatch. They need retail to abstain on Nov 17 to print 600K warrants to cover their short position (56% of float).THE PLAN: Vote ACTIVE AGAINST to freeze those warrants forever under Nasdaq Rule 5635(d). Armistice gets completely TRAPPED at a physical 4.99% baseline alongside retail, forcing them to protect our shares to save themselves.RECORD DATE: SEPT 21. Get your 16-digit control number from IBKR. No abstentions (Ex. 3.2 quorum trap). VOTE AGAINST PROP . Market physics are absolute when supply is ZERO

0 · Reply

SpanishSpolied75 Sep. 15 at 9:08 AM

$HCWB Mechanics: Price artificially frozen vs science (TOBI/TRBC, 100% Alopecia Q4, Akron cashflow). • Float: 169K(split)+218K(July)=387,682 total shares. • Short Ammunition: Fund shorted 100% physical shares; only 135,001 left in magazine. • Cost: Crushing 463% borrow fee. Financial suicide for shorts. • The Shield: Fund holds 600K common warrants. Want retail to abstain Nov17 Special Meeting (Prop 1) to dilute 23% and shield shorts against Q4 data. Objective: Keep price depressed. 🎯 TIMELINE: 1. Record Date (Sept 21): Hold shares to vote. 2. Nasdaq Compliance (Sept 22): End delisting monitoring. 100% eligible for institutions. 3. Prop 1 (Oct 1): Get 16-digit control code from broker. VOTE NO (Rule 5635d) to kill the 600K warrants. No warrants = shorts (56% of total float) left naked. When Q4 data hits pre-market, HFT algorithms will forced-buy chasing zero supply. Do not hand them your shares. 🚀💎

0 · Reply

SpanishSpolied75 Sep. 9 at 10:41 AM

🚨 $HCWB INSIDER SCAM EXPOSED: Akron CAR-T Revenues Hidden To Force Predatory 58% Dilution! 🚨 Retail shareholders are completely defenseless. Executive insiders and affiliated hedge funds now control MORE THAN 60% of the voting power, turning the October 27 Special Meeting into a total corporate sham.Connect the dots of this premeditated asset-stripping scheme:1️⃣ The Akron Deception: On Sept 4, management signed an exclusive contract with Akron Biotech for CAR-T reagents (HCW11-006), securing immediate organic revenues. Instead of disclosing this to protect the stock, they HID it to launch the predatory Proxy dilution on Sept 8, intentionally crushing the price to scare retail ("shaking out the paper").2️⃣ The Asset Laundering: They moved the worldwide rights of HCW11-006 and the multi-billion Alopecia drug (HCW9302) to Beijing Trimmune JV for pennies ($3.5M cash) while forcing US public holders to fund the cash-burning trials of HCW11-08B and HCW11-040 under a bankruptcy

1 · Reply

bmorgan1227 Sep. 8 at 7:23 PM

$HCWB this stock is horrible

0 · Reply

Invescent Sep. 8 at 2:25 PM

$HCWB — Volume + momentum watch Scanner flagged a fresh move at $2.53. +2.43% price momentum 4.79x normal volume 32.8K volume on the move candle Watching $2.50 hold/confirmation for potential continuation. Volume expansion is the key here.

0 · Reply

Joe_088 Sep. 8 at 1:44 PM

$HCWB load until 1.24 m share closed

0 · Reply

bmorgan1227 Sep. 8 at 1:42 PM

$HCWB good news and being shorted to zero

0 · Reply

MasterOfMyDomains Sep. 8 at 1:41 PM

$HCWB Bunch of no good pumpers here

0 · Reply

KingJamesXI Sep. 8 at 1:35 PM

$HCWB I guess shorts believe an offering is coming.

1 · Reply

HCW Biologics Proxy statement: Proxy filing

2026-09-08T13:20:17.000Z - 8 days ago

HCW Biologics enters exclusive HCW11-006 distribution pact with Akron Biotech

Sep 8, 2026, 8:50 AM EDT - 8 days ago

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

Sep 8, 2026, 8:00 AM EDT - 8 days ago

HCW Biologics Proxy statement: Proxy filing

2026-09-02T13:20:22.000Z - 14 days ago

HCW Biologics receives patent allowance for alopecia areata drug

Sep 2, 2026, 9:00 AM EDT - 14 days ago

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

Aug 28, 2026, 8:00 AM EDT - 19 days ago

HCW Biologics Registration statement: Registration filing

Aug 25, 2026, 9:00 AM EDT - 22 days ago

HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

2026-08-20T19:05:21.000Z - 27 days ago

HCW Biologics files to sell 1.24M shares of common stock for holders

Aug 20, 2026, 8:00 AM EDT - 27 days ago

HCW Biologics Registration statement: Registration filing

Aug 14, 2026, 4:00 PM EDT - 4 weeks ago

HCW Biologics Earnings release: Q2 2026

Aug 14, 2026, 4:00 PM EDT - 4 weeks ago

HCW Biologics Quarterly report: Q2 2026

Aug 14, 2026, 3:15 PM EDT - 4 weeks ago

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

2026-07-29T13:15:47.000Z - 7 weeks ago

HCW Biologics announces pricing of $1.6M private placement

Jul 29, 2026, 9:06 AM EDT - 7 weeks ago

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

Jul 23, 2026, 8:00 AM EDT - 7 weeks ago

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

2026-06-30T13:00:59.000Z - 2 months ago

HCW Biologics regains compliance with Nasdaq

Jun 30, 2026, 8:25 AM EDT - 2 months ago

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

2026-06-29T23:50:16.000Z - 2 months ago

Hcw Biologics Inc trading halted, news pending

2026-06-26T13:00:19.000Z - 2 months ago

HCW Biologics announces 1-for-6 reverse stock split

Jun 26, 2026, 8:55 AM EDT - 2 months ago

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

Jun 18, 2026, 8:00 AM EDT - 3 months ago

HCW Biologics Registration statement: Registration filing

2026-06-16T11:13:07.000Z - 3 months ago

HCW Biologics announces data from first two dose cohorts of HCW9302 trial

Jun 16, 2026, 7:00 AM EDT - 3 months ago

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

Jun 15, 2026, 10:00 AM EDT - 3 months ago

HCW Biologics Transcript: AGM 2026

2026-06-08T14:26:45.000Z - 3 months ago

HCW Biologics registers to sell 5.69M shares of common stock for holders

Jun 8, 2026, 8:00 AM EDT - 3 months ago

HCW Biologics Registration statement: Registration filing

2026-05-29T12:32:52.000Z - 3 months ago

HCW Biologics price target raised to $5 from $2 at Maxim

2026-05-27T23:30:12.000Z - 3 months ago

HCW Biologics CEO buys $160K in common stock

May 27, 2026, 7:45 AM EDT - 3 months ago

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

May 22, 2026, 4:02 PM EDT - 3 months ago

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

2026-05-21T19:20:55.000Z - 3 months ago

3 Penny Stocks to Watch Now, 5/21/26

MTVA SLXN

2026-05-21T14:04:03.000Z - 3 months ago

HCW Biologics announces pricing of $4M private placement

May 21, 2026, 9:53 AM EDT - 3 months ago

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules

2026-05-16T01:04:00.000Z - 4 months ago

Why Is Penny Stock HCW Biologics (HCWB) Up Today?

May 14, 2026, 4:25 PM EDT - 4 months ago

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

2026-05-14T14:02:07.000Z - 4 months ago

HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia

May 14, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Quarterly report: Q1 2026

May 14, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Earnings release: Q1 2026

May 14, 2026, 7:30 AM EDT - 4 months ago

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

Apr 30, 2026, 4:20 PM EDT - 4 months ago

HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Apr 28, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Proxy statement: Proxy filing

2026-04-27T13:34:49.000Z - 4 months ago

HCW Biologics to file IND for HCW11-018b in first half of 2027

Apr 27, 2026, 7:30 AM EDT - 4 months ago

HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors

Apr 24, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Registration statement: Registration filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

HCW Biologics Registration statement: Registration filing

Apr 17, 2026, 8:00 AM EDT - 5 months ago

HCW Biologics Proxy statement: Proxy filing

Mar 31, 2026, 5:05 PM EDT - 5 months ago

HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

Mar 31, 2026, 8:00 AM EDT - 5 months ago

HCW Biologics Annual report: Q4 2025

Mar 31, 2026, 8:00 AM EDT - 5 months ago

HCW Biologics Earnings release: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 5 months ago

HCW Biologics Slides: Corporate presentation

Mar 17, 2026, 7:50 AM EDT - 6 months ago

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic

Mar 16, 2026, 8:00 AM EDT - 6 months ago

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances

Mar 13, 2026, 8:00 AM EDT - 6 months ago

HCW Biologics Proxy statement: Proxy filing

Mar 3, 2026, 7:00 AM EST - 6 months ago

HCW Biologics Proxy statement: Proxy filing

Mar 2, 2026, 8:00 AM EST - 6 months ago

HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter

Feb 17, 2026, 9:50 PM EST - 7 months ago

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

Feb 17, 2026, 7:00 AM EST - 7 months ago

HCW Biologics Registration statement: Registration filing

Feb 13, 2026, 8:30 AM EST - 7 months ago

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

Feb 13, 2026, 7:00 AM EST - 7 months ago

HCW Biologics Registration statement: Registration filing

Feb 11, 2026, 7:00 AM EST - 7 months ago

HCW Biologics Registration statement: Registration filing

Jan 9, 2026, 7:00 AM EST - 8 months ago

HCW Biologics Registration statement: Registration filing

Nov 18, 2025, 7:25 AM EST - 10 months ago

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

Nov 14, 2025, 4:44 PM EST - 10 months ago

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 14, 2025, 7:00 AM EST - 10 months ago

HCW Biologics Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 10 months ago

HCW Biologics Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 10 months ago

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Oct 16, 2025, 9:25 AM EDT - 11 months ago

HCW Biologics to Participate in the 2025 Maxim Growth Summit

Sep 30, 2025, 8:45 AM EDT - 11 months ago

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

Sep 18, 2025, 9:15 AM EDT - 12 months ago

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Sep 16, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Aug 25, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

Aug 18, 2025, 2:44 PM EDT - 1 year ago

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 18, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Quarterly report: Q2 2025

Aug 18, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Earnings release: Q2 2025

Jun 27, 2025, 7:45 AM EDT - 1 year ago

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

Jun 26, 2025, 7:55 AM EDT - 1 year ago

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

Jun 4, 2025, 8:20 AM EDT - 1 year ago

HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech

May 15, 2025, 6:14 PM EDT - 1 year ago

HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results

May 15, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Quarterly report: Q1 2025

May 15, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Earnings release: Q1 2025

May 13, 2025, 8:01 PM EDT - 1 year ago

HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

May 13, 2025, 8:30 AM EDT - 1 year ago

HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization

May 13, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Registration statement: Registration filing

May 9, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Registration statement: Registration filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Proxy statement: Proxy filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Proxy statement: Proxy filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Registration statement: Registration filing

Apr 1, 2025, 4:35 PM EDT - 1 year ago

HCW Biologics Announces 1-for-40 Reverse Stock Split

Mar 28, 2025, 3:30 PM EDT - 1 year ago

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Mar 28, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Annual report: Q4 2024

Mar 28, 2025, 8:00 AM EDT - 1 year ago

HCW Biologics Earnings release: Q4 2024

Mar 6, 2025, 6:55 AM EST - 1 year ago

HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements

Feb 26, 2025, 7:00 AM EST - 1 year ago

HCW Biologics Proxy statement: Proxy filing

Feb 21, 2025, 7:00 AM EST - 1 year ago

HCW Biologics Proxy statement: Proxy filing

Feb 11, 2025, 7:00 AM EST - 1 year ago

HCW Biologics Proxy statement: Proxy filing

Feb 3, 2025, 7:15 AM EST - 1 year ago

HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial

Jan 17, 2025, 7:00 AM EST - 1 year ago

HCW Biologics Transcript: AGM 2025

Jan 15, 2025, 7:00 AM EST - 1 year ago

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Dec 23, 2024, 8:10 AM EST - 1 year ago

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

Nov 18, 2024, 9:27 PM EST - 1 year ago

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

Nov 18, 2024, 7:00 AM EST - 1 year ago

HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate

Nov 14, 2024, 4:40 PM EST - 1 year ago

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 14, 2024, 7:00 AM EST - 1 year ago

HCW Biologics Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

HCW Biologics Earnings release: Q3 2024

Aug 23, 2024, 4:30 PM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction

Aug 14, 2024, 4:35 PM EDT - 2 years ago

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 14, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Earnings release: Q2 2024

May 15, 2024, 4:39 PM EDT - 2 years ago

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

May 15, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Quarterly report: Q1 2024

May 15, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Earnings release: Q1 2024

Apr 26, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Proxy statement: Proxy filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

HCW Biologics Proxy statement: Proxy filing

Apr 1, 2024, 4:10 PM EDT - 2 years ago

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

Pennywarehouse Sep. 16 at 11:26 AM

$HCWB Going to buy but at 0.66 !

0 · Reply

SpanishSpolied75 Sep. 15 at 8:00 PM

0 · Reply

SpanishSpolied75 Sep. 15 at 9:08 AM

0 · Reply

SpanishSpolied75 Sep. 9 at 10:41 AM

1 · Reply

bmorgan1227 Sep. 8 at 7:23 PM

$HCWB this stock is horrible

0 · Reply

Invescent Sep. 8 at 2:25 PM

0 · Reply

Joe_088 Sep. 8 at 1:44 PM

$HCWB load until 1.24 m share closed

0 · Reply

bmorgan1227 Sep. 8 at 1:42 PM

$HCWB good news and being shorted to zero

0 · Reply

MasterOfMyDomains Sep. 8 at 1:41 PM

$HCWB Bunch of no good pumpers here

0 · Reply

KingJamesXI Sep. 8 at 1:35 PM

$HCWB I guess shorts believe an offering is coming.

1 · Reply

FaithFilledTrader Sep. 8 at 1:27 PM

$HCWB $CMND 👀

0 · Reply

focafoca99 Sep. 8 at 1:26 PM

$HCWB announces an exclusive distribution agreement with Akron Biotech for its HCW11-006 cell-therapy reagent.

0 · Reply

Joe_088 Sep. 8 at 1:12 PM

$HCWB double digit stock patience ⏳

0 · Reply

Joe_088 Sep. 8 at 1:11 PM

$HCWB HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial companies

0 · Reply

KingJamesXI Sep. 8 at 1:10 PM

$HCWB distribution agreement -20 Phase 1 great news up 300% 🤦‍♂️

0 · Reply

Joe_088 Sep. 8 at 1:09 PM

$HCWB Company showed in studies that CAR-T cells manufactured using HCW11-006 as a reagent exhibited strong anti-tumor activity and enhanced antiviral potency as well as potential for lowering the cost of production of CAR-T therapies

0 · Reply

KingJamesXI Sep. 8 at 1:06 PM

$HCWB this market is crazy...

0 · Reply

Joe_088 Sep. 8 at 1:06 PM

$HCWB last time same dip then up to 3.9

0 · Reply

MasterOfMyDomains Sep. 8 at 1:04 PM

$HCWB Short it? It seems they want to dilute this bitch.

0 · Reply

FaithFilledTrader Sep. 8 at 1:03 PM

$HCWB needs more vol

1 · Reply

Joe_088 Sep. 8 at 12:59 PM

$HCWB halt coming📈

2 · Reply

KingJamesXI Sep. 8 at 12:58 PM

$HCWB smoked on that news

0 · Reply

Market Cap	3.76M
Revenue (ttm)	50,000.00
Net Income (ttm)	-7.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-15,920.00%
Debt to Equity Ratio	0.88

Volume	86,400
Avg Vol	181,474
Day's Range	N/A - N/A
Shares Out	1.84M
Stochastic %K	8%
Beta	2.37
Analysts	Strong Sell
Price Target	$30.00